Literature DB >> 29247312

Evaluation of Breast Cancer Patients with Genetic Risk in a University Hospital: Before and After the Implementation of a Heredofamilial Cancer Unit.

Miriam Lobo1, Sara López-Tarruella1, Soledad Luque2, Santiago Lizarraga2, Carmen Flores-Sánchez1, Oscar Bueno3, Jesús Solera4, Yolanda Jerez1, Ricardo González Del Val1, María Isabel Palomero1, María Cebollero5, Isabel Echavarría1, Gabriela Torres1, Miguel Martín1, Iván Márquez-Rodas6.   

Abstract

The identification of patients at risk for breast cancer by genetic testing has proven to reduce breast cancer mortality. In 2010, due to a lack of systematization in hereditary cancer assistance in our center, we implemented a multidisciplinary Heredofamilial Cancer Unit (HFCU). We analyze if the HFCU improved the rates of referrals and preventive management of breast cancer patients with genetic risk. We retrospectively compared family history records, referrals of high-risk patients to genetic counseling, and detection and management of patients with BRCA1/2 mutations in two cohorts of breast cancer patients diagnosed before (first period: 2007-2010) and after the creation of the HFCU (second period: 2010-2013). In the first period, 893 patients were included, and 902 were included in the second. Due to the inability to establish their genetic risk, 142 patients (15.9%) vs. 70 (7.8%) were excluded from analysis (p < 0.001). Among the evaluable patients, 194 (25.8%) vs. 223 (26.8%) fulfilled one or more risk criteria (p = 0.65). Family history documentation in patient's medical records (92.4 vs. 97.8%, p < 0.001) and referral rate (26.3 vs. 52%, p < 0.0001) significantly increased in the second period. Eight BRCA1/2 mutations were detected among patients referred in the first period and 17 among those referred to the HFCU. The rate of preventive surgeries in patients with BRCA mutations significantly increased in the second period (25 vs. 76.5%, p = 0.03). In conclusion, there was a clear improvement in family history records, referrals, and preventive surgeries in breast cancer patients with genetic risk after the implementation of the HFCU.

Entities:  

Keywords:  BRCA1; BRCA2; Genetic counseling; Hereditary breast cancer; Multidisciplinary approach

Mesh:

Year:  2017        PMID: 29247312     DOI: 10.1007/s10897-017-0187-3

Source DB:  PubMed          Journal:  J Genet Couns        ISSN: 1059-7700            Impact factor:   2.537


  40 in total

Review 1.  Reconsidering the family history in primary care.

Authors:  Eugene C Rich; Wylie Burke; Caryl J Heaton; Susanne Haga; Linda Pinsky; M Priscilla Short; Louise Acheson
Journal:  J Gen Intern Med       Date:  2004-03       Impact factor: 5.128

2.  Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.

Authors:  Susan M Domchek; Tara M Friebel; Christian F Singer; D Gareth Evans; Henry T Lynch; Claudine Isaacs; Judy E Garber; Susan L Neuhausen; Ellen Matloff; Rosalind Eeles; Gabriella Pichert; Laura Van t'veer; Nadine Tung; Jeffrey N Weitzel; Fergus J Couch; Wendy S Rubinstein; Patricia A Ganz; Mary B Daly; Olufunmilayo I Olopade; Gail Tomlinson; Joellen Schildkraut; Joanne L Blum; Timothy R Rebbeck
Journal:  JAMA       Date:  2010-09-01       Impact factor: 56.272

3.  Essential elements of genetic cancer risk assessment, counseling, and testing: updated recommendations of the National Society of Genetic Counselors.

Authors:  Bronson D Riley; Julie O Culver; Cécile Skrzynia; Leigha A Senter; June A Peters; Josephine W Costalas; Faith Callif-Daley; Sherry C Grumet; Katherine S Hunt; Rebecca S Nagy; Wendy C McKinnon; Nancie M Petrucelli; Robin L Bennett; Angela M Trepanier
Journal:  J Genet Couns       Date:  2011-12-02       Impact factor: 2.537

Review 4.  In brief: BRCA1 and BRCA2.

Authors:  William D Foulkes; Andrew Y Shuen
Journal:  J Pathol       Date:  2013-08       Impact factor: 7.996

Review 5.  Genetics, genomics, and cancer risk assessment: State of the Art and Future Directions in the Era of Personalized Medicine.

Authors:  Jeffrey N Weitzel; Kathleen R Blazer; Deborah J MacDonald; Julie O Culver; Kenneth Offit
Journal:  CA Cancer J Clin       Date:  2011-08-19       Impact factor: 508.702

6.  Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer.

Authors:  Nadine Tung; Nancy U Lin; John Kidd; Brian A Allen; Nanda Singh; Richard J Wenstrup; Anne-Renee Hartman; Eric P Winer; Judy E Garber
Journal:  J Clin Oncol       Date:  2016-03-14       Impact factor: 44.544

7.  Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.

Authors:  Kelly Metcalfe; Henry T Lynch; Parviz Ghadirian; Nadine Tung; Ivo Olivotto; Ellen Warner; Olufunmilayo I Olopade; Andrea Eisen; Barbara Weber; Jane McLennan; Ping Sun; William D Foulkes; Steven A Narod
Journal:  J Clin Oncol       Date:  2004-06-15       Impact factor: 44.544

8.  SEOM recommendations on the structure and operation of hereditary cancer genetic counseling units (HCGCUs).

Authors:  Enrique Lastra-Aras; Luis Robles-Díaz; Carmen Guillén-Ponce; Emilio Alba; Juan-Jesús Cruz
Journal:  Clin Transl Oncol       Date:  2012-08-22       Impact factor: 3.405

9.  Value of database linkage: are patients at risk of familial colorectal cancer being referred for genetic counselling and testing?

Authors:  C Wong; P Gibbs; J Johns; I Jones; I Faragher; E Lynch; F Macrae; L Lipton
Journal:  Intern Med J       Date:  2007-10-03       Impact factor: 2.048

10.  Most patients with colorectal tumors at young age do not visit a cancer genetics clinic.

Authors:  Lucia I H Overbeek; Nicoline Hoogerbrugge; Joannes H J M van Krieken; Fokko M Nagengast; Theo J M Ruers; Marjolijn J L Ligtenberg; Rosella P M G Hermens
Journal:  Dis Colon Rectum       Date:  2008-08       Impact factor: 4.585

View more
  1 in total

1.  Genetic Counseling Referral Rates in Long-Term Survivors of Triple-Negative Breast Cancer.

Authors:  Carlos H Barcenas; Maryam N Shafaee; Arup K Sinha; Akshara Raghavendra; Babita Saigal; Rashmi K Murthy; Ashley H Woodson; Banu Arun
Journal:  J Natl Compr Canc Netw       Date:  2018-05       Impact factor: 11.908

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.